Antigen-Clustered Nanovaccine Achieves Long-Term Tumor Remission by Promoting B/CD 4 T Cell Crosstalk
Lists
Only you see this
Abstract
Current cancer vaccines using T cell epitopes activate antitumor T cell immunity through dendritic cell/macrophage-mediated antigen presentation, but they lack the ability to promote B/CD4 T cell crosstalk, limiting their anticancer efficacy. We developed antigen-clustered nanovaccine (ACNVax) to achieve long-term tumor remission by promoting B/CD4 T cell crosstalk. The topographic features of ACNVax were achieved using an iron nanoparticle core attached with an optimal number of gold nanoparticles, where the clusters of HER2 B/CD4 T cell epitopes were conjugated on the gold surface with an optimal intercluster distance of 5-10 nm. ACNVax effectively trafficked to lymph nodes and cross-linked with BCR, which are essential for stimulating B cell antigen presentation-mediated B/CD4 T cell crosstalk <i>in vitro</i> and <i>in vivo</i>. ACNVax, combined with anti-PD-1, achieved long-term tumor remission (>200 days) with 80% complete response in mice with HER2<sup>+</sup> breast cancer. ACNVax not only remodeled the tumor immune microenvironment but also induced a long-term immune memory, as evidenced by complete rejection of tumor rechallenge and a high level of antigen-specific memory B, CD4, and CD8 cells in mice (>200 days). This study provides a cancer vaccine design strategy, using B/CD4 T cell epitopes in an antigen clustered topography, to achieve long-term durable anticancer efficacy through promoting B/CD4 T cell crosstalk.
BibTeX
@inproceedings{li2024antigen,
author = {Chengyi Li and Ryan M. Clauson and Luke F. Bugada and Fang Ke and Bing He and Zhixin Yu and Hongwei Chen and Binyamin Jacobovitz and Hongxiang Hu and Polina Chuikov and Brett Hill and Syed Rizvi and Yudong Song and Kai Sun and Pasieka Axenov and Daniel Huynh and Xinyi Wang and Lana X. Garmire and Yu L. Lei and Irina Grigorova and Fei Wen and Marília Cascalho and Wei Gao and Duxin Sun},
title = {{Antigen-Clustered Nanovaccine Achieves Long-Term Tumor Remission by Promoting B/CD 4 T Cell Crosstalk}},
booktitle = {ACS},
year = {2024},
doi = {10.1021/acsnano.3c13038},
}Loading related content...